Hims and Hers Stock Surges 35%: GLP-1 Momentum Fuels Rebound Despite Regulatory and Revenue Headwinds
A potential shift in momentum is suggested by Hims & Hers Health's spectacular recovery following months of decline due to renewed...
Quick overview
- Hims & Hers Health stock has rebounded sharply, rising around 30% this week due to renewed optimism around its GLP-1 weight-loss strategy.
- The company has broken above its 50-day moving average, indicating improved short- to medium-term momentum, but faces longer-term resistance near the 100-day moving average.
- Management expects prescription volumes for GLP-1 treatments like Wegovy to exceed 100,000 per month, enhancing its market position amid regulatory scrutiny.
- Despite the positive momentum, a strategic shift to prioritize FDA-approved drugs may create a one-time revenue headwind of $65 million in Q1.
A potential shift in momentum is suggested by Hims & Hers Health’s spectacular recovery following months of decline due to renewed excitement for their GLP-1 weight-loss approach.
Rebound Gains Strength
Hims & Hers Health stock has been under pressure since October, but sentiment has shifted in recent weeks. After an initial rebound in early March, the stock is gaining further traction, rising around 35% this week and pushing above the $25 level.
From a technical perspective, HIMS has broken above its 50-day moving average, signaling improving short- to medium-term momentum. However, it remains below the 100-day moving average near $27.50, suggesting that longer-term resistance still caps the upside.
HIMS Chart Daily – Overtaking the 50 SMA
GLP-1 Strategy Drives Momentum
The rally is largely tied to renewed optimism around the company’s GLP-1 weight-loss offering. Investors are increasingly focused on Hims’ ability to scale its U.S. platform using FDA-approved treatments from Novo Nordisk, particularly Wegovy and Ozempic.
Management has indicated that prescription volumes for Wegovy could exceed 100,000 per month, highlighting the potential to capture meaningful share in a rapidly expanding market. The shift toward branded, FDA-approved drugs also strengthens credibility compared to compounded alternatives.
Strategic Shift and Regulatory Pressure
In March 2026, the company announced a strategic pivot in its U.S. weight-loss business. While Wegovy and Ozempic will be broadly available on its platform, compounded semaglutide will now be limited to cases where clinically necessary.
This shift was reinforced on April 14, when Hims confirmed it would prioritize distributing FDA-approved Wegovy in response to increasing regulatory scrutiny. While strategically sound, the transition is expected to create a one-time $65 million revenue headwind in Q1 due to delayed shipments.
Other Drivers and Growth Trends
The recent rally may also reflect a recovery in sentiment following earlier data-breach concerns, along with a potential short squeeze in a heavily traded name.
On the growth front, Hims continues to expand internationally, with revenue rising დაახლოებით 400% in 2025 to $134 million following acquisitions such as ZAVA and Livewell.
Conclusion
Hims & Hers is showing renewed bullish momentum, driven by its GLP-1 pivot and improving sentiment. However, technical resistance and near-term revenue headwinds suggest that sustaining the rally will depend on execution and continued growth in prescription volumes.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Related Posts
Save